Merck has taken two important steps towards its goal of achieving eight new cardiovascular drug approvals by 2030, presenting promising data for two potential blockbusters at the ACC meeting.
Merck & Co. has achieved trial success for two of its biggest pipeline hopes in cardiovascular medicine, adding weight to its efforts to build a multi-blockbuster presence in the field.
The company achieved better-than-expected Phase III results for its pulmonary arterial hypertension candidate sotatercept and also reported strong Phase IIb...
While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.
The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.
Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.
